» Articles » PMID: 18458989

Minocycline for the Treatment of Sarcoidosis: is the Mechanism of Action Immunomodulating or Antimicrobial Effect?

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2008 May 7
PMID 18458989
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

A 47-year-old female was diagnosed to have pulmonary, ocular, and nodular-type muscular sarcoidosis. Seven years later, nodules developed in all limb muscles. She received minocycline 200 mg daily, which resulted in an obvious reduction of the muscular sarcoidosis with a significant decrease in the serum angiotensin-converting enzyme level. Nine months later, the minocycline was discontinued, thus resulting in a rapid recurrence of the disease. The immediate readministration of minocycline again resulted in a prompt improvement. We detected Propionibacterium acnes within the granulomas in the affected muscle by an immunohistochemistry. More interestingly, we found a decrease in the circulating levels of interleukin-12 p40 and interferon-inducible protein-10 during the minocycline therapy. The minocycline therapy may be effective for sarcoidosis and the fact that the disease rapidly relapsed after discontinuation of the minocycline administration suggests that the mechanism of action in this case may be immunomodulating but not antimicrobial effect.

Citing Articles

The Role of in Sarcoidosis: From Antigen to Treatable Trait?.

Kraaijvanger R, Veltkamp M Microorganisms. 2022; 10(8).

PMID: 36014067 PMC: 9415339. DOI: 10.3390/microorganisms10081649.


Gastric Cancer with Multiple Lymph Node Enlargement at the Time of the Sarcoidosis Diagnosis.

Tanaka Y, Tokubayashi Y, Kikuchi M, Fujii S, Kusaka T, Shibuya S Intern Med. 2021; 60(20):3225-3229.

PMID: 33967139 PMC: 8580756. DOI: 10.2169/internalmedicine.7218-21.


Environmental Risk Factors for Sarcoidosis.

Judson M Front Immunol. 2020; 11:1340.

PMID: 32676081 PMC: 7333358. DOI: 10.3389/fimmu.2020.01340.


Development of Propionibacterium acnes-associated Sarcoidosis During Etanercept Therapy.

Isshiki T, Matsuyama H, Sakamoto S, Honma N, Mikami T, Shibuya K Intern Med. 2019; 58(10):1473-1477.

PMID: 30626837 PMC: 6548918. DOI: 10.2169/internalmedicine.2086-18.


Is there any association between Sarcoidosis and infectious agents?: a systematic review and meta-analysis.

Esteves T, Aparicio G, Garcia-Patos V BMC Pulm Med. 2016; 16(1):165.

PMID: 27894280 PMC: 5126827. DOI: 10.1186/s12890-016-0332-z.


References
1.
Hata M, Sugisaki K, Miyazaki E, Kumamoto T, Tsuda T . Circulating IL-12 p40 is increased in the patients with sarcoidosis, correlation with clinical markers. Intern Med. 2007; 46(17):1387-93. DOI: 10.2169/internalmedicine.46.6278. View

2.
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L . The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001; 137(1):69-73. DOI: 10.1001/archderm.137.1.69. View

3.
Ishige I, Usui Y, Takemura T, Eishi Y . Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet. 1999; 354(9173):120-3. DOI: 10.1016/S0140-6736(98)12310-3. View

4.
Agostini C, Cassatella M, Zambello R, Trentin L, Gasperini S, Perin A . Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol. 1998; 161(11):6413-20. View

5.
Thong Y, Ferrante A . Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. Clin Exp Immunol. 1979; 35(3):443-6. PMC: 1537627. View